Pregal Adverse Reactions

In table 2 as follows, all adverse reactions, which occurred at an incidence greater than placebo and in more than one patient are listed by class and frequency.
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
The adverse reactions listed may also be associated with the underlying disease and/or concomitant medicinal products.
In the treatment of central neuropathic pain due to spinal cord injury the incidence of adverse reactions in general, CNS adverse reactions and especially somnolence was increased.
Additional reactions reported from postmarketing experience are included in italics in the list as follows. (See Table 2.)

Click on icon to see table/diagram/image

Concerning discontinuation of long-term treatment of pregabalin, data suggest that the incidence and severity of withdrawal symptoms may be dose-related.
Paediatric population: The pregabalin safety profile observed was similar to that observed in the adult studies of patients with epilepsy. The most common adverse events observed were somnolence, pyrexia, upper respiratory tract infection, increased appetite, weight increased, and nasopharyngitis.